Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
about
Erythropoiesis-stimulating agents for myelodysplastic syndromesHypomethylating agents for patients with myelodysplastic syndromeErythropoiesis-stimulating agents for myelodysplastic syndromesHypomethylating agents for patients with myelodysplastic syndromeEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studySafety and efficacy of azacitidine in myelodysplastic syndromesUse of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesA Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeDecitabine in the treatment of myelodysplastic syndromesNew molecularly targeted therapies for lung cancerA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersTargeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyDefining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive TherapiesMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementAlteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical ImplicationsHigh-throughput sequencing for biology and medicineBeyond hypomethylating agents failure in patients with myelodysplastic syndromesThe cancer epigenome: its origins, contributions to tumorigenesis, and translational implicationsNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeInfections in myelodysplastic syndromesHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionMyelodysplastic syndromes: what do hospitalists need to know?Epigenetics meets radiation biology as a new approach in cancer treatmentClinical Results of Hypomethylating Agents in AML TreatmentDNMT3A Mutations in Acute Myeloid LeukemiaRecurrent DNMT3A mutations in patients with myelodysplastic syndromesDNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Epigenetic Therapeutics: A New Weapon in the War Against CancerRefractory anemia with ring sideroblasts and RARS with thrombocytosisOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaDecitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivoFeasibility of therapy with hypomethylating agents in patients with renal insufficiencyA comparison of azacitidine and decitabine activities in acute myeloid leukemia cell linesEquitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptomeOxidative stress induces monocyte necrosis with enrichment of cell-bound albumin and overexpression of endoplasmic reticulum and mitochondrial chaperones
P2860
Q24186244-64BAEA01-0489-45B6-A397-7CF6EE8D026EQ24186276-9BCC5864-A15A-4CB9-80D7-AE2091C18875Q24202526-363A17F7-2D7E-4CEA-87E6-789668E6955BQ24236549-DED9684D-310A-441C-B7C7-6186BFC7A12FQ24563021-DA449830-F531-4057-8EF5-CBCE5709CDA3Q24596561-75F6218B-0F96-41FE-AAA2-428A832B7C17Q24605618-25A83E33-509B-4D27-A282-E4EB0C2984B3Q24608659-F87B07A2-F4E2-4223-AEF2-5D69061D600BQ24622700-0FA843F7-5D79-42A8-AA78-046BEDC3B2DEQ24628329-DF0FABA8-C7D1-4250-B7E1-2B9A64F8C792Q24632949-D6545DBC-DE66-4CE7-B356-A7E572C93C92Q24641906-156AACD7-1650-45EA-851D-1D2F407C3B0EQ24680988-3CD730BC-08D3-408F-BD78-69FD4443A224Q26743743-330DB7F3-81F0-4C84-ADB1-D7D8346424E4Q26745731-729945DC-193D-45F6-8C46-7A51E7B8B849Q26749421-C36BFEAE-8896-4FB3-91F2-1966151CB840Q26749870-922A668A-09FD-4273-AA53-038EBB80A7E9Q26772235-512681EE-177C-49C0-B7C5-F7DC9C328A1AQ26796240-E668B04D-BE59-4541-83D3-29314D364969Q26797616-1350311F-5657-4303-B2C2-CEBC2A1D4EBBQ26823498-0C645581-74F2-433B-9478-5C69B6FA922EQ26827079-A2733518-97D7-4468-BE7B-C53BA41092A5Q26828751-5AA362C5-39DF-4561-97FA-28E0D3FDA4A4Q26829132-9B9FAB64-D46B-461A-8F42-1B683CA2BAC2Q26859275-9DFFCDD5-F490-46AB-90AF-959558E07D49Q26994739-B8913B32-E5EC-47F4-8260-57D7B18538E2Q27011372-42665231-DE68-4BB6-A977-42A0AE122AB8Q27014984-1D647B4F-68F4-4992-A72F-6B60981B036DQ27022725-0FD76B47-6576-4180-9627-BBF730999AAAQ27559610-123950F0-E00D-41E3-8111-54C64B7D0D35Q27851629-B1645710-100C-41D0-9191-1376F6917132Q27851689-9F03879A-E5BC-42E4-81DC-40DBD890D028Q28072370-44B4CF0E-7F29-4632-9A8A-57A9BDF08208Q28083238-2879034E-9A9D-40F5-9FA9-0AA3D37E3F95Q28084813-02986308-7E7C-406B-9CCA-1275C81914C2Q28263221-E72A4B3F-A634-4050-856E-47D046AC991DQ28283836-9CEEB14B-1DE3-4A87-BA04-E4DBD56BAD2CQ28472733-EA517C5A-BE67-48C7-957C-0FAED32294AAQ28475641-85921250-6392-44C8-81BD-907479536186Q28488971-5015C772-8F58-43C7-8976-4E8A891DC138
P2860
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Randomized controlled trial of ...... e cancer and leukemia group B.
@ast
Randomized controlled trial of ...... e cancer and leukemia group B.
@en
Randomized controlled trial of ...... e cancer and leukemia group B.
@nl
type
label
Randomized controlled trial of ...... e cancer and leukemia group B.
@ast
Randomized controlled trial of ...... e cancer and leukemia group B.
@en
Randomized controlled trial of ...... e cancer and leukemia group B.
@nl
prefLabel
Randomized controlled trial of ...... e cancer and leukemia group B.
@ast
Randomized controlled trial of ...... e cancer and leukemia group B.
@en
Randomized controlled trial of ...... e cancer and leukemia group B.
@nl
P2093
P356
P1476
Randomized controlled trial of ...... e cancer and leukemia group B.
@en
P2093
Alice B Kornblith
Bayard L Powell
Bercedis L Peterson
Carlos M DeCastro
Charles A Schiffer
Douglas Nelson
Erin P Demakos
James F Holland
John Ellerton
Lewis R Silverman
P304
P356
10.1200/JCO.2002.04.117
P407
P577
2002-05-01T00:00:00Z